

December 4, 2009

BioComber Co., Ltd.
Chugai Pharmaceutical Co., Ltd.

Conclusion of a license agreement between BioComber and Chugai on patents related to PURESYSYSTEM[®]

BioComber Co., Ltd. (Head Office: Bunkyo-ku, Tokyo; President and CEO; Jun Yamada; hereafter, "BioComber") and Chugai Pharmaceutical Co., Ltd. (Head Office: Chuo-ku, Tokyo; President: Osamu Nagayama; hereafter, "Chugai") concluded a license agreement pertaining to "Process for producing peptides by using *in vitro* transcription/translation system." a patent owned by BioComber on November 30, 2009.

The content of the agreement is as follows: Chugai will use PURESYSYSTEM[®], a reconstituted *Escherichia coli in vitro* translation system owned by BioComber, to step up the drug discovery research of antibodies and other substances. Since this system can be optimized for each purpose of experiments, it is expected to efficiently promote a variety of drug discovery research. Chugai will pay a license fee to BioComber.

Jun Yamada, President and CEO of BioComber, has stated as follows: "We are delighted that Chugai will use our PURESYSYSTEM[®] to carry out drug discovery research. We hope that this technology will contribute to the development of biopharmaceuticals including antibody drugs."

Dr. Hisafumi Okabe, Vice President, General Manager of Research Division of Chugai, has stated as follows: "PURESYSYSTEM[®] is one of the useful technologies, and we will aggressively utilize for the global development of antibody drugs. We are placing high hopes on the outcomes of using this Japan-originated technology."

Chugai will use BioComber's PURESYSYSTEM[®] to carry out research to discover new drugs, and the two companies will work to enhance the quality of research and expedite the process.

About BioComber

BioComber is a reagent manufacturing company established in June 2009. It deals with a group of products focusing on the PURESYSYSTEM[®] technology including the synthesis of proteins incorporated with nonnatural amino acids and the detection of inter-protein interactions, etc.

Name: BioComber Co., Ltd.

Address of head office: 4-33-16 Sengoku, Bunkyo-ku, Tokyo

Established: June 8, 2009

Capital: ¥10,000

Representative: Jun Yamada, President and CEO

Home Page: <http://www.biocomber.co.jp>

About Chugai

Chugai Pharmaceutical, specialized in prescription pharmaceuticals and based in Tokyo, is one of Japan's leading research-based pharmaceutical companies with strengths in biotechnology products.

Since the start of the strategic alliance with Roche in October 2002, Chugai is actively involved in prescription pharmaceutical R&D activities in Japan and abroad as an important member of the Roche Group. Specifically, Chugai is working to develop innovative products with global applications, focusing on the disease areas of oncology, renal disease, and bone and joint.

In Japan, Chugai's research facilities in Gotemba and Kamakura are collaborating to develop new pharmaceuticals and Ukima is conducting research for technology development for industrial production.

Overseas, Chugai Pharma USA and Chugai Pharma Europe are engaged in clinical development activities in the United States and Europe.

The consolidated sales in 2008 of Chugai totalled 326.9 billion yen and the operating profit was 51.6 billion yen. We are aiming at the consolidated sales of 460 billion yen and operating profit of 800 billion yen in 2012, as stated in new mid-term business plan "Sunrise 2012".

Additional information is available on the Internet at <http://www.chugai-pharm.co.jp/>.

Name: Chugai Pharmaceutical Co., Ltd.

Address of head office: 2-1-1 Nihonbashi-Muromachi, Chuo-ku, Tokyo

Foundation: 1925

Established: 1943

Capital: ¥72,967,000,000 (As of December 31, 2008)

Representative: Osamu Nagayama, President and CEO

Home Page: <http://www.chugai-pharm.co.jp/>

BioComber Co., Ltd.

President and CEO

Jun Yamada

TEL: 03-5319-2860 FAX: 03-5319-2960

E-Mail: junyamada@biocomber.co.jp

Chugai Pharmaceutical Co., Ltd.

Corporate Communications Dept.

Corporate Communications Group

TEL: 03-3273-0881 FAX: 03-3281-6607

E-Mail: pr@chugai-pharm.co.jp

Reference

About PURESYSTEM®

PURESYSTEM® (Protein Synthesis Using Recombinant Elements System) is the world's first reconstituted cell-free protein synthesis technology developed by the Ueda Group of the University of Tokyo. (US patent: No. 7,118,883; EU patent: No. 1319074; Japanese patent: No. 4061043).